2022 began on a mixed note, with COVID-19 testing sales again making up for slowly recovering Pharmas – continue to be impacted by biosimilar erosion and pandemic, and the weakness in some core drugs. While its COVID-19 solutions are expected to take a severe hit in the coming months, it should be offset by the expected recovery in the core businesses. Moreover, the unchanged long-term potential of innovative offerings in Pharmas, supports our positive recommendation on the Swiss giant.

25 Apr 2022
Full-year outlook maintained despite Q1 beat

Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Full-year outlook maintained despite Q1 beat
- Published:
25 Apr 2022 -
Author:
Amandeep Goyal -
Pages:
4 -
2022 began on a mixed note, with COVID-19 testing sales again making up for slowly recovering Pharmas – continue to be impacted by biosimilar erosion and pandemic, and the weakness in some core drugs. While its COVID-19 solutions are expected to take a severe hit in the coming months, it should be offset by the expected recovery in the core businesses. Moreover, the unchanged long-term potential of innovative offerings in Pharmas, supports our positive recommendation on the Swiss giant.